Top-News
Biotechnologie USA

Ionis Pharmaceuticals Inc Aktie

Aktie
WKN:  A2ACMZ ISIN:  US4622221004 US-Symbol:  IONS
28,17 €
+1,09 €
+4,03%
09:31:44 Uhr
Depot/Watchlist
Aktienanzahl *
158,96 Mio.
Marktkapitalisierung *
4,30 Mrd. €
Streubesitz
-
Index-Zugehörigkeit
Nasdaq Composite Index
IR-Website
zur Website
*Stand: 11.03.2025

Ionis Pharmaceuticals Inc News

20.03.25 - BNP
Quantencomputing-Aktien, Konjunktur- und Ergebnissorgen - Calling USA
In unserer Live-​Schalte nach Silicon Valley diskutieren wir heute unter anderem über Quantencomputing-​Aktien. Wie steht es um Firmen wie IonQ, D-Wave oder Rigetti und was ...
20.03.25 - BNP
Quantencomputing-Aktien, Konjunktur- und Ergebnissorgen - Calling USA
In unserer Live-​Schalte nach Silicon Valley diskutieren wir heute unter anderem über Quantencomputing-​Aktien. Wie steht es um Firmen wie IonQ, D-Wave oder Rigetti und was ...
20.03.25 - BNP Paribas
Quantencomputing-Aktien, Konjunktur- und Ergebnissorgen - Calling USA
In unserer Live-​Schalte nach Silicon Valley diskutieren wir heute unter anderem über Quantencomputing-​Aktien. Wie steht es um Firmen wie IonQ, D-Wave oder Rigetti und was ...
13.01.25 - PR Newswire
Ionis enters new chapter in 2025 as commercial-stage biotech with multiple independent product launches anticipated and continued late-stage pipeline momentum
Ionis enters new chapter in 2025 as commercial-​stage biotech with multiple independent product launches anticipated and continued late-​stage pipeline momentum PR Newswire
08.01.25 - PR Newswire
Ionis to present at 43rd Annual J.P. Morgan Healthcare Conference
Ionis to present at 43rd Annual J.P. Morgan Healthcare Conference PR Newswire
19.12.24 - PR Newswire
TRYNGOLZA™ (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to diet
TRYNGOLZA™ (olezarsen) approved in U.S. as first-​ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to diet PR Newswire
07.11.24 - PR Newswire
Ionis to present at upcoming investor conferences
Ionis to present at upcoming investor conferences PR Newswire
06.11.24 - PR Newswire
Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome
Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome PR Newswire
06.11.24 - PR Newswire
Ionis reports third quarter 2024 financial results
Ionis reports third quarter 2024 financial results PR Newswire
04.11.24 - PR Newswire
Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE
Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE PR Newswire
23.10.24 - PR Newswire
Ionis to hold third quarter 2024 financial results webcast
Ionis to hold third quarter 2024 financial results webcast PR Newswire
21.10.24 - PR Newswire
WAINZUA (eplontersen) recommended for approval in the EU by CHMP for the treatment of adults with polyneuropathy associated with hereditary transthyretin-mediated amyloidosis
WAINZUA (eplontersen) recommended for approval in the EU by CHMP for the treatment of adults with polyneuropathy associated with hereditary transthyretin-​mediated amyloidosis ...
03.10.24 - PR Newswire
New positive donidalorsen data to be presented at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
New positive donidalorsen data to be presented at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting PR Newswire
01.10.24 - PR Newswire
Zilganersen granted U.S. FDA Fast Track designation for people living with Alexander disease
Zilganersen granted U.S. FDA Fast Track designation for people living with Alexander disease PR Newswire
09.09.24 - PR Newswire
Ionis announces pricing of $500.3 million public offering
Ionis announces pricing of $500.3 million public offering PR Newswire
09.09.24 - PR Newswire
Ionis announces proposed public offering of common stock
Ionis announces proposed public offering of common stock PR Newswire
28.08.24 - PR Newswire
Ionis to present at upcoming investor conferences
Ionis to present at upcoming investor conferences PR Newswire
01.08.24 - PR Newswire
Ionis reports second quarter 2024 financial results
Ionis reports second quarter 2024 financial results PR Newswire
31.07.24 - PR Newswire
Alcyone Therapeutics Announces Continued Enrollment Approval from FDA of the PIERRE Pivotal IDE Clinical Study of the ThecaFlex DRx™ System for Administration of nusinersen
Alcyone Therapeutics Announces Continued Enrollment Approval from FDA of the PIERRE Pivotal IDE Clinical Study of the ThecaFlex DRx™ System for Administration of nusinersen ...
22.07.24 - PR Newswire
Ionis announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndrome
Ionis announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndrome PR Newswire

Newssuche

Videos

newspaper
30.04.25 +3,37%
Technical Trading: Cotton Long Chance
Cotton Long Typ: Turbo Open End WKN: VP6N8D Hebel: 3,80 Laufzeit: OpenEnd Einstieg: Market ... Mehr »